Neulasta

Fresenius Kabi introduces pegfilgrastim biosimilar for cancer patients in US
Fresenius Kabi introduces pegfilgrastim biosimilar for cancer patients in US
Pharmaceutical Business Review
Fresenius Kabi
Stimufend
pegfilgrastim
biosimilars
Neulasta
Amgen
cancer
Flag link:
Amgen's Neulasta gains another biosimilar competitor as sales slip
Amgen's Neulasta gains another biosimilar competitor as sales slip
Endpoints
Amgen
Neulasta
Fresenius Kabi
biosimilars
FDA
Stimufend
Flag link:
Amneal scores third biosimilar approval in three months
Amneal scores third biosimilar approval in three months
Biopharma Reporter
Amneal
FDA
biosimilars
pegfilgrastim
Fylnetra
Amgen
Neulasta
Flag link:
Amgen's Neulasta banner draws OPDP’s second letter of 2021
Amgen's Neulasta banner draws OPDP’s second letter of 2021
RAPS.org
Amgen
Neulasta
FDA
OPDP
advertising
Flag link:
If Biosimilars Are Struggling, Someone Forgot to Tell Coherus BioSciences
If Biosimilars Are Struggling, Someone Forgot to Tell Coherus BioSciences
Motley Fool
biosimilars
FDA
Coherus Biosciences
Neulasta
Amgen
Flag link:
It took a 3-year struggle, but Novartis finally gets a green light on their copycat to Amgen's big blockbuster
It took a 3-year struggle, but Novartis finally gets a green light on their copycat to Amgen's big blockbuster
Endpoints
Novartis
FDA
Amgen
Neulasta
biosimilars
Ziextenzo
cancer
Flag link:
Under copycat attack, Amgen punches back with its own biosimilars
Under copycat attack, Amgen punches back with its own biosimilars
Fierce Pharma
Amgen
biosimilars
generics
Sensipar
Neulasta
Neupogen
Flag link:
A Key Novartis Drug Could Be Delayed — Why This Stock Is Cheering
A Key Novartis Drug Could Be Delayed — Why This Stock Is Cheering
Investors Business Daily
Coherus Biosciences
Novartis
Udenyca
Neulasta
biosmilars
Flag link:
Coherus' Neulasta biosimilar surprises with strong early uptake
Coherus' Neulasta biosimilar surprises with strong early uptake
Biopharma Dive
Coherus Biosciences
Neulasta
biosimilars
Udenyca
Amgen
Flag link:
Sandoz resubmission puts Amgen's Neulasta at further risk of competition
Sandoz resubmission puts Amgen's Neulasta at further risk of competition
Biopharma Dive
FDA
Novartis
biosimilars
Sandoz
Amgen
Neulasta
Flag link:
Spectrum yanks marketing application for Neulasta rival after FDA demands more data
Spectrum yanks marketing application for Neulasta rival after FDA demands more data
Endpoints
Spectrum Pharmaceuticals
FDA
lung cancer
poziotinib
Neulasta
Flag link:
Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount
Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount
Reuters
Coherus Biosciences
Amgen
biosimilars
Neulasta
Flag link:
Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price
Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price
Endpoints
Coherus
Neulasta
Mylan
biosimilars
Amgen
Flag link:
Mylan biosimilar to stress test Amgen Neulasta franchise, analyst predicts
Mylan biosimilar to stress test Amgen Neulasta franchise, analyst predicts
Biopharma Dive
Amgen
Neulasta
biosimilars
Flag link:
Could Amgen soften the Neulasta biosimilar blow with an Alexion buy?
Could Amgen soften the Neulasta biosimilar blow with an Alexion buy?
Fierce Pharma
Amgen
biosimilars
Neulasta
Alexion
M&A
Flag link:
Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval
Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval
Fierce Pharma
FDA
Fulphila
Mylan Labs
biosimilars
Amgen
Neulasta
Flag link:
Coherus BioSciences Re-Submits BLA for Neulasta (Pegfilgrastim) Biosimilar Candidate
Coherus BioSciences Re-Submits BLA for Neulasta (Pegfilgrastim) Biosimilar Candidate
CP Wire
Coherus Biosciences
Neulasta
CHS-1701
Mylan
Biocon
Flag link:
Coherus BioSciences Re-Submits BLA for Neulasta (Pegfilgrastim) Biosimilar Candidate
Coherus Biosciences
Neulasta
CHS-1701
Mylan
Biocon
Flag link:
What to Expect From Amgen, Inc. in 2018
What to Expect From Amgen, Inc. in 2018
Motley Fool
Amgen
Enbrel
Neulasta
Aranesp
Epogen
Neupogen
Prolia
Repatha
CAR-T
Flag link:
Will 2018 Be Amgen Inc.'s Best Year Yet?
Will 2018 Be Amgen Inc.'s Best Year Yet?
Motley Fool
Amgen
Enbrel
Aranesp
Neulasta
Epogen
Flag link:

Pages